ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
Neoadjuvant axitinib to allow partial nephrectomy of cT2a renal tumours
A phase 2 study published in the British Journal of [...]
Avelumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
New drug combination for advanced kidney cancer
Scientists have identified a promising new drug for renal cell [...]
Targeted therapies with immunotherapies in kidney cancer
The following video is an interview with Professor Thomas Powles [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Dalantercept plus axitinib combination for advanced kidney cancer
The results from a recent phase II study comparing a [...]
ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib
The results from the following study were presented at the [...]
ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC
The results from the following study were presented at the [...]
ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)
Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]
